Evidence map›Paper›PMID 27410922›Full record

Trial reportThe New England journal of medicine2016

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Rudolph M Navari, Rui Qin, Kathryn J Ruddy, Heshan Liu, Steven F Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M Lafky, Charles L Loprinzi

5 registry-linked trialsOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 200 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed, 20 pooled it
46.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02116530 phase3completednot on this map

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial

TypeinterventionalSponsorAlliance for Clinical Trials in OncologyRan2014 to 2017Enrolled401ConditionsHematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol SpecificArmsOlanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron, plus dexamethasone, plus fosaprepitant or aprepitant)
NCT02970643 naunknown statusnot on this map

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting

TypeinterventionalSponsorHee Jun KimRan2016 to 2017Enrolled48ConditionsChemotherapy-induced Nausea and VomitingArmsOlanzapine, Palonosetron
NCT04535141 phase3completednot on this mapstarted 2020, after this paper: background citation

Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant

TypeinterventionalSponsorUNC Lineberger Comprehensive Cancer CenterRan2020 to 2022Enrolled91ConditionsChemotherapy-induced Nausea and VomitingArmsOlanzapine 5 MG, Placebo
NCT05805800 phase3completednot on this mapstarted 2023, after this paper: background citation

Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent Nausea and Vomiting Induced by Chemotherapy: A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial

TypeinterventionalSponsorXingchen PengRan2023 to 2024Enrolled275ConditionsChemotherapy-induced Nausea and VomitingArms5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone
NCT07743827 narecruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of an Olanzapine Based Dexamethasone-sparing Regimen in Breast Cancer Patients With Metabolic-risk Factors: A Randomized, Controlled Trial

TypeinterventionalSponsorAlexandria UniversityRan2026 to 2027Enrolled90ConditionsOlanzapine, Breast Cancer, DexamethasoneArmsPantoprazole, olanzapine, Dexamethasone
3 · Its place in the literature

Who cites it

200 citing papers in PubMed, 20 syntheses or guidelines pooled it, 431 citations in OpenAlex.

  1. Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Clinical benefits of adding olanzapine to 5-HTInternational journal of clinical oncology · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

140 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Rudolph M NavariFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Rui QinFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Kathryn J RuddyFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Heshan LiuFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Steven F PowellFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Madhuri BajajFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Leah DietrichFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
David BiggsFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Jacqueline M LafkyFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Charles L LoprinziFrom Indiana University School of Medicine-South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care-Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware-Christiana Care NCORP, Newark, DE (D.B.).
Mayo Clinic in Arizona · USMayo Clinic · USChristiana Care Health System · USGundersen Lutheran Hospital · USIllinois CancerCare · USIndiana University South Bend · USNorth Central College · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9M
WORKER PROTECTION AGAINST AIRBORNE INFLUENZA - A PILOT STUDYM01RR007122 · NCRR · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUNDLEY, WILLIAM GREGORY · 1992 to 2010
$35.2M
Wisconsin NCI Community Oncology Research Program (WiNCORP)UG1CA189956 · NCI · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI ADEDAYO A ONITILO, Kurt Oettel · 2014 to 2026
$32.3M
ZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4M
YOGA, IMMUNE FUNCTION, AND HEALTHM01RR000034 · NCRR · OHIO STATE UNIVERSITY · PI PESAVENTO, TODD · 1985 to 2008
$22.7M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
Delaware Christiana Care NCORPUG1CA189819 · NCI · CHRISTIANA CARE HEALTH SERVICES, INC. · PI GREGORY A MASTERS · 2014 to 2026
$21.6M
Sanford Community Cancer Program of the North Central Plains (NCORP)UG1CA189825 · NCI · SANFORD RESEARCH/USD · PI Daniel Almquist, SAMUEL J. MILANOVICH · 2014 to 2026
$13.6M
DULUTH COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035269 · NCI · ESSENTIA INSTITUTE OF RURAL HEALTH · PI NIKCEVICH, DANIEL A · 1985 to 2014
$10.7M
NCI NIH HHS 5UG1CA189819NCI NIH HHS CA035269NCI NIH HHS P30 CA012197NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA108961NCI NIH HHS U10 CA035269NCI NIH HHS U10 CA180790NCI NIH HHS U10CA180790NCI NIH HHS U10 CA180867NCI NIH HHS UG1 CA189819NCI NIH HHS UG1 CA189823NCI NIH HHS UG1CA189823NCI NIH HHS UG1 CA189825NCI NIH HHS UG1CA189825NCI NIH HHS UG1 CA189830NCI NIH HHS UG1CA189830NCI NIH HHS UG1 CA189956NCI NIH HHS UG1CA189956NCRR NIH HHS M01 RR000034NCRR NIH HHS M01 RR000585NCRR NIH HHS M01 RR007122
6 · The paper itself

Abstract

backgroundWe examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.

methodsIn a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin. The doses of the three concomitant drugs administered before and after chemotherapy were similar in the two groups. The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4. Nausea prevention was the primary end point; a complete response (no emesis and no use of rescue medication) was a secondary end point.

resultsIn the analysis, we included 380 patients who could be evaluated (192 assigned to olanzapine, and 188 to placebo). The proportion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after chemotherapy (74% vs. 45%, P=0.002), the period from 25 to 120 hours after chemotherapy (42% vs. 25%, P=0.002), and the overall 120-hour period (37% vs. 22%, P=0.002). The complete-response rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P<0.001), 67% versus 52% (P=0.007), and 64% versus 41% (P<0.001), respectively. Although there were no grade 5 toxic effects, some patients receiving olanzapine had increased sedation (severe in 5%) on day 2.

conclusionsOlanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02116530.).

Indexed as

AdultAgedAged, 80 and overAntiemeticsAntineoplastic AgentsAprepitantBenzodiazepinesDexamethasoneDouble-Blind MethodDrug Therapy, CombinationFemaleHumansIntention to Treat AnalysisMaleMiddle AgedMorpholinesAntiemeticsAntineoplastic AgentsAprepitantBenzodiazepinesDexamethasonefosaprepitantMorpholinesOlanzapine

Identifiers

PMID27410922
PMCPMC5344450
OpenAlexW2460792208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.